Bausch Health Companies Inc. (TSX: BHC)

Canada flag Canada · Delayed Price · Currency is CAD
10.93
-0.12 (-1.09%)
Dec 30, 2024, 10:57 AM EST
10.63%
Market Cap 4.06B
Revenue (ttm) 12.80B
Net Income (ttm) -240.47M
Shares Out n/a
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,101
Open 10.91
Previous Close 11.05
Day's Range 10.78 - 10.98
52-Week Range 5.45 - 15.43
Beta 0.77
Analysts n/a
Price Target n/a
Earnings Date Feb 20, 2025

About Bausch Health Companies

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,270
Stock Exchange Toronto Stock Exchange
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.

Financial numbers in USD Financial Statements

News

Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.

17 days ago - Reuters

Bausch & Lomb edges higher after confirming sales process

Bausch & Lomb (BLCO) confirms sales process for eyecare company, exploring potential sale options as part of full separation from Bausch Health Companies...

18 days ago - Seeking Alpha

Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors

Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors

18 days ago - GuruFocus

Bausch + Lomb Responds to Rumors of a Potential Sale

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement...

18 days ago - Business Wire

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...

18 days ago - Accesswire

Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

19 days ago - Benzinga

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affili...

19 days ago - Business Wire

Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News

Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome issues. Click for more on BLCO and BHC.

23 days ago - Seeking Alpha

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation...

25 days ago - Accesswire

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

We are bullish on undervalued Bausch Health Companies (BHC) for 2024 and beyond, citing spin-off benefits, innovation, and market expansion. See more here.

27 days ago - Seeking Alpha

Bausch Health Appoints New Chief Medical Officer and Head of R&D

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medi...

4 weeks ago - Accesswire

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.

6 weeks ago - Reuters

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...

6 weeks ago - Accesswire

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and ben...

6 weeks ago - Accesswire

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

6 weeks ago - Business Wire

Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Bausch Health Companies Inc.

2 months ago - Seeking Alpha

Bausch Health raises 2024 revenue guidance

2 months ago - Seeking Alpha

Bausch Health Announces Third Quarter 2024 Results

Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1 Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic...

2 months ago - Accesswire

Bausch + Lomb Announces Third-Quarter 2024 Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quar...

2 months ago - Business Wire

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterolog...

2 months ago - Accesswire

Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces

Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported.

2 months ago - Benzinga

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. ...

2 months ago - Business Wire